NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1311.60 -13.70 (-1.03%)

28.59% Gain from 52W Low

119.6K NSE+BSE Volume

NSE 23 Jun, 2025 9:32 AM (IST)

109,462.3

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Dividend

Dr. Reddy's Laboratories Ltd. has an upcoming dividend of ₹8.00 per share due on 10 Jul 2025 See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

03 Nov 2020

1311.60

-1.03%

Dr. Reddy`s Laboratories Limited

Dr. Reddy's Laboratories Ltd.

SMC online

Dr Reddys Labs reported on weak Q2 outcome, misses estimates Consolidated total income jumped 2% to Rs 4910.90 crore in Q2 September 2020 as against Rs 4812.80 crore in Q2 September 2019. Profit before tax (PBT) jumped 12.48% to Rs 862.10 crore in Q2 September 2020 as against Rs 766.40 crore in Q2 September 2019. Tax expense for...

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

03 Nov 2020

1311.60

-1.03%

DR. REDDY'S LABORATARIES

Buy: Dr. Reddy's Laboratories Ltd.

Target

Geojit BNP Paribas

EBITDA rose 10.1% QoQ (-13.1% YoY), despite margin contracting 20bps QoQ (-440bps YoY) to 25.1%, impacted by forex losses, higher staff costs. Subsequently, net profit rose 29.8% QoQ (-30.3% YoY) to Rs....

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

03 Nov 2020

1311.60

-1.03%

Axis Alpha: Dr Reddys Labs (BUY)

Buy: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

We recommend a BUY on Dr. Ready's Laboratories Ltd with a Target Price of Rs 5,280, an upside of 8% from CMP of Rs 4,890 and Stop Loss Rs 4,600.

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

29 Oct 2020

1311.60

-1.03%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

Q2 revenues grew 2.0% YoY to | 4911 crore (I-direct estimate: | 4564 crore) mainly due to strong growth across segments partly offset by high base effect in Q2FY20 (divestiture of certain proprietary products). US revenues grew 28.5% YoY to | 1833 crore on the back of rupee depreciation and new product launches. Domestic revenues grew 21.5% YoY to | 912 crore due to Wockhardt integration and Covid products. Europe revenues grew 35.8% YoY to | 375 crore due to new launches and currency tailwinds. PSAI segment posted a robust 19.7% YoY growth to | 851 crore. EBITDA margins...

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

29 Oct 2020

1311.60

-1.03%

Result Update:Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Axis Direct

We expect Consol Revenue amd Consol PAT CAGR 10.9% and 22.1% respectively over the period FY20-FY23E. Therfore, we recommend BUY Target Price INR 6,200 for DRRD (PE multiple of 28x to FY23E earnings).

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

28 Oct 2020

1311.60

-1.03%

Dr Reddys Labs

Accumulate: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Dolat Capital

Dr Reddy's reported a decent 2Q with strong performance in India (Wockhardt portfolio integration and COVID products) and US (new launches). However, lower export incentive, higher price erosion, change in product mix and adverse currency impacted gross margins (54% in 2Q vs 56% in 1Q), in line with estimates. Adjusting for the impairment charge of Rs781mn for intangibles, EBITDA margins came in line at 24.3%. Further, lower tax rate (deferred tax benefit) aided profitability at Rs7.6bn (vs our estimate of Rs5.7bn)....

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

28 Oct 2020

1311.60

-1.03%

Dr Reddy's Labs (ADD): All-round beat; H2 catalysts tracking well

Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

Dr Reddy's (DRRD) reported a Q2 EBITDA beat of 13% led by better operating leverage across markets.

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

14 Oct 2020

1311.60

-1.03%

Monthly Update - IPM growth crawling forward to low single-digit

Accumulate: Dr. Reddy's Laboratories Ltd.

Prabhudas Lilladhar

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Dr. Reddy's Laboratories Ltd.

05 Oct 2020

1311.60

-1.03%

Event Update - gKuvan in US: Silent launch, strong potential - Accumulate

Accumulate: Dr. Reddy's Laboratories Ltd.

Prabhudas Lilladhar

Dr. Reddy's Laborato.. has an average target of 1343.25 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

01 Oct 2020

1311.60

-1.03%

Company Update:Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

The recent approval for gRevlimid could create a peak oppportunity of USD $250 mn USD $300 revenue per year during the period FY23E-FY25E. Therfore, we have increased our Target Price INR 6,200 for DRRD (PE multiple of 28x to FY23E earnings).

Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr

Is Dr. Reddy's Laboratories Ltd. worth buying?

511 Votes:

Buy 78.28%

Sell 12.13%

Hold 9.59%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf